Core Viewpoint - Kangchen Pharmaceutical (603590.SH) has received approval from the National Medical Products Administration for clinical trials of its innovative drug KC1036, aimed at treating advanced recurrent or metastatic esophageal squamous cell carcinoma in combination with PD-1 antibodies and platinum-based chemotherapy [1] Group 1: Product Development - KC1036 is a self-developed Class 1 innovative chemical drug with global intellectual property rights held by the company [1] - The drug exerts anti-tumor activity by inhibiting multiple targets such as VEGFR2 and AXL, demonstrating strong vascular targeting of VEGFR and inhibiting tumor cell growth [1] - Inhibiting AXL can enhance the host's anti-tumor immune response, thereby preventing immune evasion by tumors [1] Group 2: Clinical Research - KC1036 is currently undergoing clinical research for multiple indications, including gastrointestinal tumors, thymic tumors, and pediatric rhabdomyosarcoma [1] - Over 300 subjects have been enrolled in the clinical studies for KC1036 to date, with existing results showing outstanding anti-tumor activity, as well as good safety and tolerability [1]
康辰药业(603590.SH):KC1036联合PD-1抗体和含铂化疗一线治疗晚期复发或转移性食管鳞癌获批临床试验